FDA Approves Expanded Labeling For Campath® To Include First Line Treatment For Leading Form Of Adult Leukemia
Bayer Schering Pharma AG, Germany, and Genzyme Corp., USA, announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for Campath® (alemtuzumab) and granted regular approval for single agent Campath for the treatment of B cell chronic lymphocytic leukemia (B-CLL).
